Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852903 | PMC |
| http://dx.doi.org/10.1007/s11356-020-11617-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Sustained H/Fluorouracil-Releasing Suppository for High-efficacy and Low-Toxicity Hydrogenochemotherapy of Colon Cancer.
Adv Healthc Mater
January 2025
Shanghai Key Laboratory of Hydrogen Science & Center of Hydrogen Science, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
To attenuate the intestinal toxicity of chemotherapeutic drugs from rectal suppositories and enhance their chemotherapeutic outcome is greatly significant, but maintains a challenge. In this work, a new strategy of local synergistic hydrogenochemotherapy is proposed to attenuate side effects and enhance therapeutic efficacy based on the anti-cancer selectivity and normal cells-protecting effect of H, and construct a novel anti-cancer formulation of rectal suppository (5-FU/CSN@FAG) by fatty acid glycerides (FAG) encapsulating 5-fluorouracil (5-FU, a first-line drug for colorectal cancer treatment) and cerium silicide nanoparticles (CSN) with a sustained hydrolytic H release behavior which is synchronous with 5-FU release. The 3-week treatment with the suppository once a day can not only completely eradicate colon tumors without tumor recurrence after suppository administration withdrawal, but also efficiently protect the intestinal tract from chemotherapeutic damage.
View Article and Find Full Text PDFPreclinical assessment of splicing modulation therapy for ABCA4 variant c.768G>T in Stargardt disease.
Commun Med (Lond)
January 2025
Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Stargardt disease type 1 (STGD1) is a progressive retinal disorder caused by bi-allelic variants in the ABCA4 gene. A recurrent variant at the exon-intron junction of exon 6, c.768G>T, causes a 35-nt elongation of exon 6 that leads to premature termination of protein synthesis.
View Article and Find Full Text PDFCardiovascular Complications Following Acute Methadone Poisoning in Patients with and Without a History of Long-term Methadone Use.
J Res Pharm Pract
December 2024
Department of Clinical Toxicology, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: Given the prevalence of methadone poisoning, this study was conducted to compare the cardiovascular complications following acute methadone poisoning in patients with and without a history of long-term methadone use.
Methods: In this retrospective study, information related to patients with acute methadone poisoning hospitalized at Al-Zahra and Khorshid hospitals in Isfahan-Iran was collected from hospital archives and analyzed. Patients were divided into two groups with and without a history of long-term methadone use.
Prevalence and Risk Factors of Medication Errors in Enteral Tube Feeding Among ICU Patients: A Comprehensive Cross-Sectional Analysis.
J Res Pharm Pract
December 2024
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: Most of the patients who are admitted to the intensive care unit (ICU) are forced to feed and use nutrition and medicine through an implanted tube. When administering medication through enteral feeding tubes, it is essential to be cautious, as some drugs may not be suitable due to interactions with feeding formulas or adverse effects when crushed. Some errors during drug gavage can lead to feeding tube blockage, reduced drug effectiveness, or drug toxicity.
View Article and Find Full Text PDFAutomatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid.
Ther Adv Drug Saf
January 2025
Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France.
Background: Reporting serious adverse events (SAEs) is crucial to reduce or avoid toxicities that can lead to major consequences for patient's health due to treatments tested in clinical trials. Its exhaustiveness is often inadequate, and we observe discrepancies between data published by pharmacovigilance organizations and clinical databases.
Objectives: While the process of reconciliation aims at reducing these differences, it remains a very time-consuming and imprecise task.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!